This study aims to isolate and identify the Pasteurella multocida(Pm)that caused re-spiratory infections in cattle at a farm in Beijing,and to clarify the biological characteristics of the pathogen,including its serotype,drug resistance,pathogenicity,and genomic features.For this pur-pose,nasopharyngeal swabs and tissue samples were collected from an infected cow for bacterial i-solation and purification,16S rRNA gene amplification,capsular serotyping,virulence gene detec-tion,and whole-genome sequencing of the isolated strain.The results showed that after bacterial i-solation and purification,biochemical tests,and PCR identification,a type A P.multocida strain named"Pm WZ01"was identified.The virulence gene amplification revealed that the Pm WZ01 ge-nome contained the tadD,nanH,ompA,exbB,exbD,and fur genes.Whole-genome sequencing determined that the Pm WZ01 strain had a genome size of 2 383 021 bp with a GC content of 40.28％,containing 56 tRNAs,19 rRNAs,155 pseudogenes,three genomic islands,five prophages,and 55 carbohydrate-active enzyme genes.CARD annotation analysis found one PBP3 resistance gene and two EF-Tu resistance genes.VFDB and PHI-base annotation analysis identified 582 viru-lence factor-related genes and 888 phenotypic mutation genes,etc.Phylogenetic tree analysis revealed that the Pm WZ01 strain is most closely related to the Pm-3 strain(CP014618.1)from Changchun,China,the P1933 strain(CP132898.1)from the UK,and the HB01 strain(CP006976.1)from Hubei,China,belonging to the same clade.This study completed the isolation and identifica-tion of a type A P.multocida strain as well as the analysis of its biological characteristics and whole-genome sequencing,providing a theoretical basis for the prevention and control research of bovine type A P.multocida disease.

This study aims to isolate and identify the Pasteurella multocida(Pm)that caused re-spiratory infections in cattle at a farm in Beijing,and to clarify the biological characteristics of the pathogen,including its serotype,drug resistance,pathogenicity,and genomic features.For this pur-pose,nasopharyngeal swabs and tissue samples were collected from an infected cow for bacterial i-solation and purification,16S rRNA gene amplification,capsular serotyping,virulence gene detec-tion,and whole-genome sequencing of the isolated strain.The results showed that after bacterial i-solation and purification,biochemical tests,and PCR identification,a type A P.multocida strain named"Pm WZ01"was identified.The virulence gene amplification revealed that the Pm WZ01 ge-nome contained the tadD,nanH,ompA,exbB,exbD,and fur genes.Whole-genome sequencing determined that the Pm WZ01 strain had a genome size of 2 383 021 bp with a GC content of 40.28％,containing 56 tRNAs,19 rRNAs,155 pseudogenes,three genomic islands,five prophages,and 55 carbohydrate-active enzyme genes.CARD annotation analysis found one PBP3 resistance gene and two EF-Tu resistance genes.VFDB and PHI-base annotation analysis identified 582 viru-lence factor-related genes and 888 phenotypic mutation genes,etc.Phylogenetic tree analysis revealed that the Pm WZ01 strain is most closely related to the Pm-3 strain(CP014618.1)from Changchun,China,the P1933 strain(CP132898.1)from the UK,and the HB01 strain(CP006976.1)from Hubei,China,belonging to the same clade.This study completed the isolation and identifica-tion of a type A P.multocida strain as well as the analysis of its biological characteristics and whole-genome sequencing,providing a theoretical basis for the prevention and control research of bovine type A P.multocida disease.

Standardized reporting is a crucial factor affecting the use of patient guidelines （PGs）， particularly in the reporting and presentation of recommendations. This paper introduced the current status of PG reporting， including the research on PG content and presentation formats， and provided comprehensive recommendations for PG reporting from aspects such as overall framework， recommendations， presentation format， and readability. First， the presentation of PG recommendations should include clearly defined clinical questions， recommendations and their rationale， and guidance on how patients should implement the interventions； for specific content in the PG， such as level of evidence， level of recommendation， it is recommended to explain in text the reasons for giving different levels of recommendation， i.e.， to present the logic behind giving the level of recommendation to the patient； additional information needed in the recommendation framework should be supplemented by tracing references or authoritative textbooks and literature that support the recommendations. Subsequently， the PG text should be written based on the Reporting Checklist for Public Versions of Guidelines （RIGHT-PVG） reporting framework. Finally， to enhance readability and comprehension， it is recommended to refer to the Patient Education Materials Assessment Tool （PEMAT） for translating PG content. To enhance the readability of PGs， it is suggested to present the PG content in a persona-lized and layered manner.

Since the concept of patient versions of guidelines （PVGs） was introduced into China， several PVGs have been published in China， but we found that there is a big difference between the concept of PVG at home and abroad， and the reason for this difference has not been reasonably explained， which has led to ambiguity and even misapplication of the PVG concept by guideline developers. By analyzing the background and purpose of PVGs， and the understanding of the PVG concept by domestic scholars， we proposed the term patient guidelines （PGs）. This refers to guidelines developed under the principles of evidence-based medicine， centered on health issues that concern patients， and based on the best available evidence， intended for patient use. Except for the general attribute of providing information or education， which is typical of common health education materials， PGs also provide recommendations and assist in decision-making， so PGs include both the patient versions of guidelines （PVG） as defined by the Guidelines International Network （GIN） and "patient-directed guidelines"， i.e. clinical practice guidelines resulting from the adaptation or reformulation of recommendations through clinical practice guidelines.

At present， the process and methodology of patient guidelines （PGs） development varies greatly and lacks systematic and standardised guidance. In addition to the interviews with PG developers， we have sorted out the relevant methodology for the adaptation and development of existing clinical practice guideline recommendations and facilitated expert deliberations to achieve a consensus， so as to finally put forward a proposal for guidance on the process and methodology for the development of PGs. The development of PGs can be divided into the preparation stage， the construction stage， and the completion stage in general， but the specific steps vary according to the different modes of development of PGs. The development process of Model 1 is basically the same as the patient version of the guideline development process provided by the International Guidelines Network， i.e.， team formation， screening of recommendations， guideline drafing， user testing and feedback， approval and dissemination. The developer should also first determine the need for and scope of translating the clinical practice guideline into a patient version during the preparation phase. Model 2 adds user experience and feedback to the conventional clinical practice guideline development process （forming a team， determining the scope of the PG， searching， evaluating and integrating evidence， forming recommendations， writing the guideline， and expert review）. Based on the different models， we sort out the process and methods of PG development and introduce the specific methods of PG development， including how to identify the clinical problem and how to form recommendations based on the existing clinical practice guidelines， with a view to providing reference for guideline developers and related researchers.

Objective: To observe the safety and clinical efficacy of tumor antigen-pulsed dendritic cell(DC) vaccine in treatment of advanced malignant tumor.Methods: Ninety-one patients with non-small cell lung cancer,colon and rectal cancer,melanoma,renal carcinoma,breast cancer and other malignant tumors were enrolled in this study.All patients met the selecting standard and signed informed consent.Human dendritic cells were obtained from peripheral blood monocytes by culturing them with granulocyte macrophage-colony stimulating factor and interleukin-4.DC vaccine was prepared from tumor antigen pulsed immature dendritic cells in vitro.Patients received the vaccine therapy once every week and one cycle was defined as once every week for 3 weeks.Results: All the patients received 96 cycles of DC vaccine treatment.Symptoms of toxicity included fever,shivering,aching pain of muscle,asthenia,itching,stifle and transient fatigue;most of the symptoms automatically recovered.Clinical efficacy of the treatment was evaluated in 76 patients.Thirty-one of the 76 patients were stable after treatment and 45 were in progressive situation,with the clinical benefiting rate being 40.8%.Eighty-five patients were followed up.The median time for progression was 2.6 months;the overall survival time was 0.9-30.6 months;and the median survival period was 4.5 months,with the one year survival rate being 9.2%.Conclusion: The results suggest that the DC vaccine therapy is well tolerated in treating patients with advanced malignant tumors and has satisfactory clinical benefit;the clinical value of DC vaccine therapy needs to be further observed.